Rational Advisors LLC Purchases 10,465 Shares of Stryker Co. (NYSE:SYK)

Share on StockTwits

Rational Advisors LLC raised its position in shares of Stryker Co. (NYSE:SYK) by 4,136.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,718 shares of the medical technology company’s stock after acquiring an additional 10,465 shares during the period. Stryker makes up 0.9% of Rational Advisors LLC’s portfolio, making the stock its 22nd biggest holding. Rational Advisors LLC’s holdings in Stryker were worth $2,318,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Vanguard Group Inc. lifted its stake in Stryker by 2.1% during the second quarter. Vanguard Group Inc. now owns 26,735,288 shares of the medical technology company’s stock worth $5,496,241,000 after purchasing an additional 555,327 shares during the period. Northern Trust Corp lifted its stake in Stryker by 0.5% during the second quarter. Northern Trust Corp now owns 3,922,830 shares of the medical technology company’s stock worth $806,455,000 after purchasing an additional 19,248 shares during the period. Nuveen Asset Management LLC lifted its stake in Stryker by 20,218.6% during the second quarter. Nuveen Asset Management LLC now owns 2,596,110 shares of the medical technology company’s stock worth $533,708,000 after purchasing an additional 2,583,333 shares during the period. Morgan Stanley lifted its stake in Stryker by 3.4% during the second quarter. Morgan Stanley now owns 1,826,762 shares of the medical technology company’s stock worth $375,547,000 after purchasing an additional 59,305 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Stryker by 3.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,357,591 shares of the medical technology company’s stock worth $279,094,000 after purchasing an additional 44,907 shares during the period. Institutional investors own 73.13% of the company’s stock.

Shares of NYSE SYK traded up $1.55 during mid-day trading on Wednesday, hitting $201.73. 1,165,898 shares of the stock were exchanged, compared to its average volume of 1,230,970. The company has a market cap of $74.74 billion, a P/E ratio of 27.60, a PEG ratio of 2.45 and a beta of 0.80. The stock’s fifty day simple moving average is $211.50 and its two-hundred day simple moving average is $205.96. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.35 and a current ratio of 2.18. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $223.45.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.90 by $0.01. The company had revenue of $3.59 billion during the quarter, compared to analyst estimates of $3.58 billion. Stryker had a net margin of 23.55% and a return on equity of 25.33%. The company’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $1.69 earnings per share. As a group, equities research analysts predict that Stryker Co. will post 8.23 earnings per share for the current fiscal year.

SYK has been the subject of a number of analyst reports. BMO Capital Markets set a $216.00 price target on shares of Stryker and gave the stock a “hold” rating in a research note on Friday, July 26th. Robert W. Baird raised their price target on shares of Stryker from $239.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Bank of America raised their price target on shares of Stryker from $220.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. UBS Group raised their price target on shares of Stryker from $220.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, July 29th. Six equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $220.17.

In other news, VP M Kathryn Fink sold 28,690 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $220.97, for a total transaction of $6,339,629.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Srikant M. Datar sold 350 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $215.00, for a total transaction of $75,250.00. Following the completion of the sale, the director now directly owns 6,844 shares of the company’s stock, valued at approximately $1,471,460. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,524 shares of company stock valued at $14,731,927. Company insiders own 7.20% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: The role of implied volatility with call option volume

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

NTT Docomo  versus Echostar  Head to Head Contrast
NTT Docomo versus Echostar Head to Head Contrast
United States Steel  Now Covered by Deutsche Bank
United States Steel Now Covered by Deutsche Bank
Zacks Investment Research Upgrades InterContinental Hotels Group  to Hold
Zacks Investment Research Upgrades InterContinental Hotels Group to Hold
BioLife Solutions Inc  Receives Average Recommendation of “Buy” from Analysts
BioLife Solutions Inc Receives Average Recommendation of “Buy” from Analysts
ScanSource, Inc.  Given Average Rating of “Buy” by Brokerages
ScanSource, Inc. Given Average Rating of “Buy” by Brokerages
Rocky Brands  Stock Rating Lowered by ValuEngine
Rocky Brands Stock Rating Lowered by ValuEngine


 
© 2006-2019 Zolmax.